Background:
The current prospective, randomized, controlled REVERSE-FLOW trial aims to systematically examine the effect of the
glycoprotein (GP) IIb/IIIa inhibitors on infarct size in patients with STEMI and NSTEMI and angiographic evidence of
no-reflow.
Trial Registration No:
SNCTP000003611
Trial Status:
active
Enrolling Centers:
5
Core Study Team:
+Team Ärzte
Invasive Kardiologie